Assyro AI

Orange Book product · Brand (NDA)

OXBRYTA

VOXELOTOR

Brand (NDA)NDA 213137DISCN GLOBAL BLOOD THERAPS

At a glance

Oct 14, 2022

Approved

Brand (NDA)

Application

Not listed

TE code

13

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Oct 14, 2022

    3 yr 9 mo ago

  2. Today

  3. Exclusivity ends · ODE-394

    Orphan-drug exclusivity (7 years)

    Dec 17, 2028

    in 2 yr 6 mo

  4. Patent 10017491 expires

    Listed drug product patent expiration.

    Dec 28, 2032

    in 6 yr 7 mo

  5. Patent 10034879 expires

    Listed drug substance patent expiration.

    Dec 28, 2032

    in 6 yr 7 mo

  6. Patent 10806733 expires

    Listed drug substance patent expiration.

    Dec 28, 2032

    in 6 yr 7 mo

  7. Patent 9018210 expires

    Listed drug substance patent expiration.

    Nov 25, 2033

    in 7 yr 7 mo

  8. Patent 9248199 expires

    Listed method-of-use patent (U-2676) expiration.

    Jan 29, 2034

    in 7 yr 9 mo

  9. Patent 9248199 expires

    Listed method-of-use patent (U-2715) expiration.

    Jan 29, 2034

    in 7 yr 9 mo

  10. Patent 10722502 expires

    Listed drug product patent expiration.

    Feb 06, 2035

    in 8 yr 9 mo

  11. Patent 11452720 expires

    Listed method-of-use patent (U-3459) expiration.

    Feb 06, 2035

    in 8 yr 9 mo

  12. Patent 9447071 expires

    Listed drug substance patent expiration.

    Feb 06, 2035

    in 8 yr 9 mo

  13. Patent 11020382 expires

    Listed method-of-use patent (U-3133) expiration.

    Dec 02, 2036

    in 10 yr 7 mo

  14. Patent 11020382 expires

    Listed method-of-use patent (U-3134) expiration.

    Dec 02, 2036

    in 10 yr 7 mo

  15. Patent 11944612 expires

    Listed method-of-use patent (U-3893) expiration.

    Dec 02, 2036

    in 10 yr 7 mo

  16. Patent 10493035 expires

    Listed drug product patent expiration.

    Oct 12, 2037

    in 11 yr 6 mo

Pharmaceutical detail

Active ingredient

VOXELOTOR

Strength

300MG

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 213137

Product number

002

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

  • ODE-394Orphan-drug exclusivity (7 years)

    Dec 17, 2028

    in 2 yr 6 mo

Listed patents (13)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10017491Dec 28, 2032in 6 yr 7 mo
Product
10034879Dec 28, 2032in 6 yr 7 mo
SubstanceProduct
10806733Dec 28, 2032in 6 yr 7 mo
Substance
9018210Nov 25, 2033in 7 yr 7 mo
SubstanceProduct
9248199Jan 29, 2034in 7 yr 9 mo
U-2676
9248199Jan 29, 2034in 7 yr 9 mo
U-2715
10722502Feb 06, 2035in 8 yr 9 mo
Product
11452720Feb 06, 2035in 8 yr 9 mo
U-3459
9447071Feb 06, 2035in 8 yr 9 mo
SubstanceProduct
11020382Dec 02, 2036in 10 yr 7 mo
U-3133
11020382Dec 02, 2036in 10 yr 7 mo
U-3134
11944612Dec 02, 2036in 10 yr 7 mo
U-3893
10493035Oct 12, 2037in 11 yr 6 mo
Product
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.